even the renown dr bruce patterson opines re LL and ctc
CytoDyn advisor and diagnostic partner IncellD founder and CEO Bruce Patterson said: “Remarkably, the new patient enrolled in the clinical trial showed a significant drop in CTC and a reduction of EMT cells, the putative metastatic cells from seven per 4mL of blood to two cells in just two weeks of treatment with leronlimab in combination with carboplatin.
“The rapid response to the treatment in a pattern that is identical to previous patients is equally as remarkable and supports a predictable method of action for this drug. Additionally, no adverse effects were observed in the clinical trials, further supporting leronlimab’s potential safety profile.”